The PACS Group, Inc. (NYSE: PACS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret them. As a healthcare holding company in the post-acute care and medical care facilities space, PACS uses SEC reports to describe its facility portfolio, credit arrangements, governance, and risk profile.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of PACS Group’s operations, financial condition, and risk factors. These filings also provide context on the company’s role as a holding company, the structure of its independent operating subsidiaries, and the separation between licensed healthcare providers and non-provider entities. AI-generated highlights can point out key sections on post-acute care operations, use of credit facilities, and lease obligations.
Current reports on Form 8-K are particularly important for PACS, given its history of restatements, credit agreement amendments, and NYSE listing updates. Recent 8-K filings have addressed topics such as forbearance and amendments under the company’s amended and restated credit agreement, events of default and related waivers, NYSE listing extensions tied to delayed SEC filings, and the completion of an independent Audit Committee investigation and related restatements. AI summaries can help users quickly understand the implications of these events.
Users can also access proxy materials such as the Definitive Proxy Statement on Schedule 14A, which outlines matters presented to stockholders at the annual meeting, including director elections, auditor ratification, and advisory votes on executive compensation. In addition, the filings page provides real-time updates from EDGAR and convenient access to other forms, such as notifications of late filings on Form 12b-25. Together, these documents offer a comprehensive view of PACS Group’s regulatory history, governance decisions, and financial reporting, with AI tools available to simplify and explain complex disclosures.
PACS Group, Inc. is identified as the issuer in a Rule 144 notice listing Jason Murray’s proposed sale of 386,667 common shares through UBS Financial Services, Inc., with an aggregate market value of $18,517,482.63 and an approximate sale date of October 16, 2026. The notice lists 158,335,612 common shares outstanding and reports prior common-stock sales by Jason Murray from August 17 through October 16, 2026.
PACS Group, Inc. officer Joshua O. Jergensen filed a notice of a proposed sale of 132,519 common shares, with an aggregate market value of $5,004,565.00. The notice lists October 14, 2026 as the approximate sale date, The Charles Schwab Corporation as broker and NYSE as the exchange. It also reports two earlier sales: 40,000 shares on August 12, 2026, valued at $1,823,688.00, and 40,000 shares on September 16, 2026, valued at $1,725,132.00.
PACS Group, Inc. Co-Founder, CEO & Chairman Jason Hulse Murray sold 36,692 shares across October 6 and 7, 2026. On October 6, he sold 28,753 shares at a weighted average of $42.9554 per share, in transactions priced from $42.53 to $43.51, and 7,222 shares at a weighted average of $43.6370 per share, in transactions priced from $43.53 to $43.79. On October 7, he sold 717 shares at $42.4800 per share. The sales were made under a Rule 10b5-1 trading plan adopted May 18, 2026.
Jason Hulse Murray, PACS Group, Inc.'s Co-Founder, CEO & Chairman, reported direct sales totaling 83,308 shares of common stock across four transactions under a Rule 10b5-1 trading plan adopted on May 18, 2026. He sold 33,032 shares on October 1, 2026, at a weighted average of $41.1255 per share; on October 2, he sold 2,596 shares at $41.7902 and 23,456 shares at $42.5931; and on October 5, he sold 24,224 shares at $42.6551. Each reported price is a weighted average.
PACS Group, Inc. (PACS) announced a planned transition in its top legal role. John Mitchell retired as Chief Legal Officer and Secretary effective September 18, 2026, and entered into a Transition and Release Agreement under which he will serve as a non-employee consultant for up to 12 months. In exchange for a release of claims and compliance with restrictive covenants, he will receive 12 months of base salary continuation, company-subsidized COBRA premiums for up to 12 months, and accelerated and continued vesting of certain restricted stock units during the consulting period, with any remaining unvested awards forfeited at its end.
Patrick J. Murphy will succeed Mitchell as Chief Legal Officer and Corporate Secretary effective September 21, 2026, overseeing the company’s legal function. PACS describes itself as a large post-acute care platform with 355 facilities across 20 states serving more than 33,400 patients daily.
PACS Group, Inc. (PACS) reported that President & COO Joshua Jergensen sold a total of 40,000 shares of common stock on September 16, 2026 in open-market transactions. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.
The transactions consisted of 36,502 shares at a weighted average price of $43.0814 per share, with trade prices ranging from $42.57 to $43.565, and 3,498 shares at a weighted average price of $43.6181 per share, with trade prices ranging from $43.575 to $43.75.
PACS Group, Inc. (PACS) is the issuer of common stock covered by a notice filed for the potential resale of restricted or control securities under Rule 144. The notice states that Mark Hancock plans to sell 155,682 shares of PACS common stock through Citigroup Global Markets Inc., with an aggregate market value of $6,612,032.49, after September 15, 2026 on the NYSE. PACS common stock outstanding is listed as 158,035,612 shares, which is a baseline figure, not the amount being sold. The filing also lists Hancock’s prior sales of PACS shares over the past three months.
PACS Group, Inc. (PACS) director and ten percent owner Mark Hancock reported open-market sales of 300,000 shares of Common Stock on September 14–15, 2026. The sales occurred in multiple transactions at weighted-average prices ranging from about $41.47 to $45.13 per share, and were effected under a Rule 10b5-1 trading plan adopted on March 11, 2026.
PACS Group, Inc. (PACS) is named as the issuer in a Form 144 filing by Mark Hancock covering proposed sales of its common stock. The notice lists up to 144,318 shares of PACS common stock to be sold through Citigroup Global Markets Inc. on the NYSE, with an aggregate market value of $6,432,859.40 as of September 14, 2026.
The filing states that Hancock originally acquired 54,626,199 shares at the formation of the issuer on March 1, 2023 for cash, and details multiple prior sales of PACS common stock over the three months from June 15, 2026 to July 15, 2026, each with specified share counts and dollar amounts.